Dementia and Alzheimer Disease

Dr Eric McDade shares information on different types of prevention trials to manage Alzheimer’s disease.

Expert neurologists share information on drugs with different mechanisms of actions that are being evaluated in clinical trials for Alzheimer’s disease.

The director of the Alzheimer’s Disease Research Center at Mayo Clinic detailed the current issues with access and affordability to critical biomarkers in the screening and monitoring of patients in Alzheimer disease trials. [WATCH TIME: 3 minutes]

The newly updated label warns patients on aducanumab about the potential risks of brain bleeding, which can be significant and life-threatening.

To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.

The director of the Alzheimer’s Disease Research Center at Mayo Clinic provided insight on new considerations for interpreting data from cognitive and functional measures in trials assessing agents for Alzheimer disease.

To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.

Here's some of what is coming soon to NeurologyLive® this week.

The director of the Alzheimer’s Disease Research Center at Mayo Clinic provided perspective on the emergence in antiamyloid therapies, assessing clinically meaningful benefit, and potential changes to trial design in the future. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending February 11, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 10, 2023.

Drs McDade and Atri discuss differences and similarities between other ongoing anti-amyloid antibody trials in Alzheimer’s disease.

Drs Cohen, Atri, and Sabbagh share data on lecanemab, an anti-amyloid beta antibody, that was presented at CTAD 2022.

The director of the Alzheimer’s Disease Research Center at Mayo Clinic discussed a recently published paper focused on the expectations and clinical meaningfulness of randomized controlled trials in Alzheimer disease. [WATCH TIME: 4 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of January 2023, compiled all into one place by the NeurologyLive® team.

Factoring in the complex nature of the disease, a group of experts provided perspectives on how clinically meaningful benefit should be viewed, stressing the importance of early intervention.

ABATE is an ongoing phase 1b/2 trial that assesses the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-24.060 in individuals with prodromal Alzheimer disease with confirmed amyloid pathology on PET.

Here's some of what is coming soon to NeurologyLive® this week.

The list of women's contributions to the field of medicine is a long one, encompassing the hard work of hundreds of individuals. To highlight some of these pioneers, NeurologyLive® has compiled a timeline of 10 of the moments that matter in the history of women in medicine.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 3, 2023.

In celebration of Women’s Physician Day, held February 3, 2022, take a look back at some of the latest conversations and news that were driven and delivered by women in neurology.

The director of the Montefiore Einstein Center for the Aging Brain provided insight on expanding the use of the 5-Cog tool, and whether it can be used for other conditions like HIV or COVID-19. [WATCH TIME: 3 minutes]

Dr Atri comments on observation of amyloid related imaging abnormalities (ARIA) seen with many Alzheimer’s disease treatments and shares his thoughts on management of ARIA.

Dr Atri discusses aducanumab, first FDA approved anti-amyloid-beta antibody for treatment of Alzheimer’s disease.

Donald Whiting, MD, chair of Allegheny Health Network’s Neurosciences Institute, provided insight on ADvance II, a multinational trial exploring the use of deep brain stimulation in patients with mild Alzheimer disease.